Gene · 2810
Papers2,367
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
41 to 60 of 2,367
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Impact of stratifin/14-3-3σ on survival and interstitial lung disease in patients with non-small cell lung cancer receiving immune checkpoint inhibitors. | Cancer Immunol Immunother | 2025 | 40616610 | PubTator, text mining | PubMed |
| From Concepts to Inhibitors: A Blueprint for Targeting Protein-Protein Interactions. | Chem Rev | 2025 | 40553022 | PubTator, text mining | PubMed |
| Stratifin Is Necessary for Spasmolytic Polypeptide-Expressing Metaplasia Development After Acute Gastric Injury. | Cell Mol Gastroenterol Hepatol | 2025 | 40280276 | PubTator, text mining | PubMed |
| Traditional Chinese medicine-based therapeutics for Pediatric pneumonia-related acute lung injury and acute respiratory distress syndrome. | Sci Rep | 2025 | 40188247 | PubTator, text mining | PubMed |
| Putative Biomarkers for Prognosis, Epithelial-to-Mesenchymal Transition, and Drug Response in Cell Lines Representing Oral Squamous Cell Carcinoma Progression. | Genes (Basel) | 2025 | 40004538 | PubTator, text mining | PubMed |
| Covalent Proximity Inducers. | Chem Rev | 2025 | 39692621 | PubTator, text mining | PubMed |
| 14-3-3σ restricts YY1 to the cytoplasm, promoting therapy resistance, and tumor progression in colorectal cancer. | Int J Cancer | 2025 | 39239852 | PubTator, text mining | PubMed |
| PMEPA1 promotes gastric cancer cell proliferation by regulating the ubiquitin-mediated degradation of 14-3-3σ and promoting cell cycle progression. | Braz J Med Biol Res | 2024 | 39607204 | PubTator, text mining | PubMed |
| The clinicopathological significance and prognostic impact of 14-3-3σ/stratifin expression on patients with surgically resectable intrahepatic cholangiocarcinoma. | Asian J Surg | 2024 | 39232956 | PubTator, text mining | PubMed |
| Targeted Protein Localization by Covalent 14-3-3 Recruitment. | J Am Chem Soc | 2024 | 39196545 | PubTator, text mining | PubMed |
| Serum stratifin measurement is useful for evaluating disease severity and outcomes in patients with acute exacerbation of interstitial lung disease: a retrospective study. | BMC Pulm Med | 2024 | 39075455 | PubTator, text mining | PubMed |
| SFN promotes renal fibrosis via binding with MYH9 in chronic kidney disease. | Eur J Pharmacol | 2024 | 38986830 | PubTator, text mining | PubMed |
| Prognostic Function and Immunologic Landscape of a Predictive Model Based on Five Senescence-Related Genes in IPF Bronchoalveolar Lavage Fluid. | Biomedicines | 2024 | 38927453 | PubTator, text mining | PubMed |
| PEMF Potentiates Doxorubicin-induced Late G2 Arrest in MDA-MB-231 Breast Cancer Cells. | Anticancer Res | 2024 | 38925852 | PubTator, text mining | PubMed |
| 14-3-3σ downregulation sensitizes pancreatic cancer to carbon ions by suppressing the homologous recombination repair pathway. | Aging (Albany NY) | 2024 | 38843383 | PubTator, text mining | PubMed |
| Somatic USP8 alteration affects the immune landscape of corticotroph pituitary adenomas- a pilot study. | Hormones (Athens) | 2024 | 38819743 | PubTator, text mining | PubMed |
| Development of a NanoBRET assay for evaluation of 14-3-3σ molecular glues. | SLAS Discov | 2024 | 38797286 | PubTator, text mining | PubMed |
| Comprehensive Bioinformatic Investigation of TP53 Dysregulation in Diverse Cancer Landscapes. | Genes (Basel) | 2024 | 38790205 | PubTator, text mining | PubMed |
| Retracted: Overexpression of 14-3-3σ Modulates Cholangiocarcinoma Cell Survival by PI3K/Akt Signaling. | Biomed Res Int | 2024 | 38550083 | PubTator, text mining | PubMed |
| Stratifin promotes the malignant progression of HCC via binding and hyperactivating AKT signaling. | Cancer Lett | 2024 | 38490326 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/2810/papers?page=3